The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Blockade of TGF-β Signaling by the TGFβR-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma
Published version of a preprint
Abstract
Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor that tends to be resistant to the ionizing radiotherapy used to treat it. Because TGF-β is a modifier of radiation responses, we conducted a preclinical study of the antitumor effects of the TGF-β receptor (TGFβR) I kinase inhibitor LY2109761 in combination with radiotherapy. LY2109761 reduced clonogenicity and increased radiosensitivity in GBM cell lines and cancer stem–like cells, augmenting the tumor growth delay produced by fractionated radiotherapy in a supra-additive manner in vivo. In an orthotopic intracranial model, LY2109761 significantly reduced tumor growth, prolonged survival, and extended the prolongation of survival induced by radiation treatment. Histologic analyses showed that LY2109761 inhibited tumor invasion promoted by radiation, reduced tumor microvessel density, and attenuated mesenchymal transition. Microarray-based gene expression analysis revealed signaling effects of the combinatorial treatments that supported an interpretation of their basis. Together, these results show that a selective inhibitor of the TGFβR-I kinase can potentiate radiation responses in glioblastoma by coordinately increasing apoptosis and cancer stem–like cells targeting while blocking DNA damage repair, invasion, mesenchymal transition, and angiogenesis. Our findings offer a sound rationale for positioning TGFβR kinase inhibitors as radiosensitizers to improve the treatment of glioblastoma. Cancer Res; 71(23); 7155–67. ©2011 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have shown that TGF-β receptor I inhibitors (SD-208) inhibit anti-angiogenesis in hepatocellular carcinoma (HCC) and glioblastoma multiforme (GBM) xenograft tumors [219,220].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [220]
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., & Vescovi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1364 · Cited by 2,570
The transcriptional network for mesenchymal transformation of brain tumours
Carro, M. S., Lim, W. K., Alvarez, M. J., Bollo, R. J., Zhao, X., Snyder, E. Y., Sulman, E. P., Anne, S. L., Doetsch, F., Colman, H., et al. (2010) · Nature · doi:10.1038/nature08712 · Cited by 1,259
Radial glia cells are candidate stem cells of ependymoma
Taylor, M. D., Poppleton, H., Fuller, C., Su, X., Liu, Y., Jensen, P., Magdaleno, S., Dalton, J., Calabrese, C., Board, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.001 · Cited by 829
Notch Promotes Radioresistance of Glioma Stem Cells
Wang, J., Wakeman, T. P., Lathia, J. D., Hjelmeland, A. B., Wang, X.-F., White, R. R., Rich, J. N., & Sullenger, B. A. (2010) · Stem Cells · doi:10.1002/stem.261 · Cited by 656
Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients
Zeppernick, F., Ahmadi, R., Campos, B., Dictus, C., Helmke, B. M., Becker, N., Lichter, P., Unterberg, A., Radlwimmer, B., & Herold-Mende, C. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0932 · Cited by 588
Cited by
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Signaling Receptors for TGF-β Family Members
Heldin, C.-H., & Moustakas, A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022053 · Cited by 711
Targeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 611
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
Self-citation
Metadata
- Authors
- Zhang, M., Kleber, S., Röhrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-Villalba, A., Debus, J., Peschke, P., Wirkner, U., Lahn, M., & Huber, P. E.
- Affiliations
- German Cancer Research Center (DE)
- Eli Lilly (United States) (US)
- Authors' Affiliations: 1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China; Departments of 2Radiation Oncology and 3Neurobiology of Brain Tumors, German Cancer Research Center (DKFZ); 4Department of Radiation Oncology, University Hospital Center, Heidelberg; 5SHG-Klinik Idar-Oberstein Klinik für Neurochirurgie, 2 Dr.-Ottmar-Kohler-Straße, Idar-Oberstein, Germany; and 6Oncology Early Clinical Investigation, Lilly Research Laboratories, Indianapolis, Indiana
- Corresponding author
- Huber, Peter E.
- ORCID
- Venue
- Cancer Research
- Published
- 2011-11-29
- Volume
- 71
- Issue
- 23
- Pages
- 7155-7167
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2045318349
- Cited by
- 249
- References
- 49
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 6 · 2023: 8 · 2022: 9 · 2021: 35 · 2020: 16 · 2019: 12 · 2018: 20 · 2017: 20 · 2016: 20 · 2015: 21 · 2014: 26 · 2013: 19 · 2012: 19
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glioblastoma, TGF-beta signaling, LY2109761, radiosensitization, radiotherapy resistance, combination therapy, cancer stem-like cells, mesenchymal transition, tumor invasion, angiogenesis, DNA repair, apoptosis, tumor microvessel density
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type I, Animals, Brain Neoplasms, DNA Damage, DNA Repair, Glioblastoma, Humans, Mice, Inbred BALB C, Neoplasm Invasiveness, Neovascularization, Pathologic, Pyrazoles, Pyrroles, Radiation Tolerance, Radiation-Sensitizing Agents, Neoplastic Stem Cells, Signal Transduction, Transforming Growth Factor beta, Mice, SCID, Apoptosis, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Xenograft Model Antitumor Assays, Cell Line, Tumor, Microarray Analysis, Protein Kinase Inhibitors, Cell Proliferation, Mice, Smad2 Protein, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blockade of TGF-β Signaling by the TGFβR-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-1212
- The paper
- Zhang, M., Kleber, S., Röhrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-Villalba, A., Debus, J., Peschke, P., Wirkner, U., Lahn, M., & Huber, P. E. (2011). Blockade of TGF-β Signaling by the TGFβR-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-1212
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.